Skip to Main Content

Contact Information

Cox Science Center 204 (0421)
Sandra Rieger, Ph.D.

Sandra Rieger, Ph.D.

  • Associate Professor
  • Principal Investigator
Department:
  • Biology
Research InterestPage 1
1. Dr. Rieger is interested in developing therapies for paclitaxel-induced peripheral neuropathy (PIPN). She has identified MMP-13 as a target of paclitaxel in the epidermis that when inhibited alleviates neuropathy/ neurotoxicity. Her lab is currently studying the mechanisms by which paclitaxel activates MMP-13, and they are determining how MMP-13 induces axon degeneration. Dr. Rieger would like to develop MMP-13 inhibitors into clinical applications for the prevention of neuropathy or the treatment of chemotherapy patients with already existing neuropathy. MMP-13 inhibition also shows efficacy in diabetic neuropathy in zebrafish and mice. She, therefore, envisions additional research on the mechanisms leading to MMP-13 -dependent diabetic neuropathy and to develop treatments for this condition. 2. Dr. Rieger is working on Anterior Gradient Protein 2, a proto-oncogene that plays a role as an antimicrobial factor in the intestine. Dr. Rieger’s team have found a similar function during mouse digit tip regeneration. One goal is to determine whether parallel functions of Agr2 also promote cancer formation.